| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A.B. Miller, H. Bartsch, P. Boffetta, L. Dragsted and H. Vainio (eds),Biomarkers in Cancer Chemoprevention
|
C. Bouchardy
|
|
2001
|
12 |
9 |
p. 1188-1188
1 p.
|
artikel
|
| 2 |
Americans may finally be reimbursed by Medicare for oral chemotherapy
|
|
|
|
12 |
9 |
p. 1184
|
artikel
|
| 3 |
And which will be the next drug to go out of the market?
|
|
|
|
12 |
9 |
p. 1185
|
artikel
|
| 4 |
Annals is going well
|
|
|
|
12 |
9 |
p. 1184
|
artikel
|
| 5 |
A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer
|
Skovsgaard, T.
|
|
|
12 |
9 |
p. 1255-1257
|
artikel
|
| 6 |
A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer
|
T. Skovsgaard
|
|
2001
|
12 |
9 |
p. 1255-1257
3 p.
|
artikel
|
| 7 |
Are drug companies manipulating publications?
|
|
|
|
12 |
9 |
p. 1183
|
artikel
|
| 8 |
Book review
|
McArdle, C.S.
|
|
|
12 |
9 |
p. 1194
|
artikel
|
| 9 |
Book review
|
Bouchardy, C.
|
|
|
12 |
9 |
p. 1188
|
artikel
|
| 10 |
Clinical-benefit response in advanced non-small-cell lung cancer:A multicentre prospective randomised phase III study of single agentgemcitabine versus cisplatinvindesine
|
J. F. Vansteenkiste
|
|
2001
|
12 |
9 |
p. 1221-1230
10 p.
|
artikel
|
| 11 |
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine* * Data presented in part at the May 2000 New Orleans meeting of the American Society of Clinical Oncology
|
Vansteenkiste, J.F.
|
|
|
12 |
9 |
p. 1221-1230
|
artikel
|
| 12 |
Contents of the next issue
|
|
|
|
12 |
9 |
p. iv
|
artikel
|
| 13 |
Copyright
|
|
|
|
12 |
9 |
p. ii
|
artikel
|
| 14 |
Corrigendum B. Glimelius. Chemoradiotherapy for rectal cancer is there an optimal combination? Ann Oncol 12 (8): 103945.
|
|
|
2001
|
12 |
9 |
p. 1334-1334
1 p.
|
artikel
|
| 15 |
Corrigendum F. Bertolini, W. Mingrone, A. Alietti, P. F. Ferrucci, E. Cocorocchio, F. Peccatori, S. Cinieri, P. Mancuso, C. Corsini, A. Burlini, E. Zucca & G. Martinelli. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 2001; 12 (7): 98790.
|
|
|
2001
|
12 |
9 |
p. 1333-1333
1 p.
|
artikel
|
| 16 |
Current and future potential roles of the platinum drugs in the treatment of ovarian cancer
|
Piccart, M.J.
|
|
|
12 |
9 |
p. 1195-1203
|
artikel
|
| 17 |
Current and future potential roles of the platinum drugs in the treatmentof ovarian cancer
|
M.J. Piccart
|
|
2001
|
12 |
9 |
p. 1195-1203
9 p.
|
artikel
|
| 18 |
D.C. Allen, Histopathology Reporting. Guidelines for SurgicalCancer
|
C. S. McArdle
|
|
2001
|
12 |
9 |
p. 1194-1194
1 p.
|
artikel
|
| 19 |
Difficult times at Johns Hopkins
|
|
|
|
12 |
9 |
p. 1185
|
artikel
|
| 20 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial
|
Köstler, W.J.
|
|
|
12 |
9 |
p. 1281-1288
|
artikel
|
| 21 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial
|
W. J. Köstler
|
|
2001
|
12 |
9 |
p. 1281-1288
8 p.
|
artikel
|
| 22 |
Editorial Board
|
|
|
|
12 |
9 |
p. iii
|
artikel
|
| 23 |
Epidemiology and survival in patients with carcinoid disease in the Netherlands
|
Quaedvlieg, P.F.H.J.
|
|
|
12 |
9 |
p. 1295-1300
|
artikel
|
| 24 |
Epidemiology and survival in patients with carcinoid disease in the Netherlands
|
P. F. H. J. Quaedvlieg
|
|
2001
|
12 |
9 |
p. 1295-1300
6 p.
|
artikel
|
| 25 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin’s disease
|
|
|
|
12 |
9 |
p. 1213-1214
|
artikel
|
| 26 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of Hodgkins disease
|
ESMO Guidelines Task Force
|
|
2001
|
12 |
9 |
p. 1213-1214
2 p.
|
artikel
|
| 27 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumours (NSGCT)
|
|
|
|
12 |
9 |
p. 1215-1216
|
artikel
|
| 28 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of mixed or non-seminomatous germ cell tumours (NSGCT)
|
ESMO Guidelines Task Force
|
|
2001
|
12 |
9 |
p. 1215-1216
2 p.
|
artikel
|
| 29 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin’s lymphoma
|
|
|
|
12 |
9 |
p. 1209-1210
|
artikel
|
| 30 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of newly diagnosed large cell non-Hodgkins lymphoma
|
ESMO Guidelines Task Force
|
|
2001
|
12 |
9 |
p. 1209-1210
2 p.
|
artikel
|
| 31 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of ovarian cancer
|
|
|
|
12 |
9 |
p. 1205-1207
|
artikel
|
| 32 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of ovarian cancer
|
ESMO Guidelines Task Force
|
|
2001
|
12 |
9 |
p. 1205-1207
3 p.
|
artikel
|
| 33 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin’s lymphoma
|
|
|
|
12 |
9 |
p. 1211-1212
|
artikel
|
| 34 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of relapsed large cell non-Hodgkins lymphoma
|
ESMO Guidelines Task Force
|
|
2001
|
12 |
9 |
p. 1211-1212
2 p.
|
artikel
|
| 35 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of testicular seminoma
|
|
|
|
12 |
9 |
p. 1217-1218
|
artikel
|
| 36 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of testicular seminoma
|
ESMO Guidelines Task Force
|
|
2001
|
12 |
9 |
p. 1217-1218
2 p.
|
artikel
|
| 37 |
ESMO Recommendations for the application of haematopoietic growth factors (hGFs)
|
|
|
|
12 |
9 |
p. 1219-1220
|
artikel
|
| 38 |
ESMO Recommendations for the application of haematopoieticgrowth factors (hGFs)
|
ESMO Guidelines Task Force
|
|
2001
|
12 |
9 |
p. 1219-1220
2 p.
|
artikel
|
| 39 |
How the fascination of cannabis misleads journalists
|
|
|
|
12 |
9 |
p. 1183
|
artikel
|
| 40 |
If this was our only anxiety about our adolescent kids?
|
|
|
|
12 |
9 |
p. 1184
|
artikel
|
| 41 |
In this issue
|
|
|
|
12 |
9 |
p. iv
|
artikel
|
| 42 |
Is there quality in clinical benefit?
|
Steer, C.B.
|
|
|
12 |
9 |
p. 1191-1193
|
artikel
|
| 43 |
Is there quality in clinical benefit?
|
C. B. Steer
|
|
2001
|
12 |
9 |
p. 1191-1193
3 p.
|
artikel
|
| 44 |
Male gonadal dysfunction in patients with Hodgkin’s disease prior to treatment
|
Rueffer, U.
|
|
|
12 |
9 |
p. 1307-1311
|
artikel
|
| 45 |
Male gonadal dysfunction in patients with Hodgkins disease prior to treatment
|
U. Rueffer
|
|
2001
|
12 |
9 |
p. 1307-1311
5 p.
|
artikel
|
| 46 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial
|
Laufman, L.R.
|
|
|
12 |
9 |
p. 1259-1264
|
artikel
|
| 47 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial
|
L. R. Laufman
|
|
2001
|
12 |
9 |
p. 1259-1264
6 p.
|
artikel
|
| 48 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy
|
Ulrich-Pur, H.
|
|
|
12 |
9 |
p. 1269-1272
|
artikel
|
| 49 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy
|
H. Ulrich-Pur
|
|
2001
|
12 |
9 |
p. 1269-1272
4 p.
|
artikel
|
| 50 |
Non-Hodgkin’s lymphoma of the testis: A retrospective study of 84 patients treated in the French anticancer centres
|
Lagrange, J.-L.
|
|
|
12 |
9 |
p. 1313-1315
|
artikel
|
| 51 |
Non-Hodgkins lymphoma of the testis: A retrospective study of 84 patients treated in the French anticancer centres
|
J.-L. Lagrange
|
|
2001
|
12 |
9 |
p. 1313-1319
7 p.
|
artikel
|
| 52 |
Patients become anxious and medical care team is overwhelmed: Anxiety about tamoxifen once again
|
|
|
|
12 |
9 |
p. 1183-1184
|
artikel
|
| 53 |
Perhaps not everyone knows that…
|
|
|
|
12 |
9 |
p. 1185-1187
|
artikel
|
| 54 |
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)
|
Punt, C.J.A.
|
|
|
12 |
9 |
p. 1289-1293
|
artikel
|
| 55 |
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)
|
C. J. A. Punt
|
|
2001
|
12 |
9 |
p. 1289-1293
5 p.
|
artikel
|
| 56 |
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
|
Beer, T.M.
|
|
|
12 |
9 |
p. 1273-1279
|
artikel
|
| 57 |
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
|
T. M. Beer
|
|
2001
|
12 |
9 |
p. 1273-1279
7 p.
|
artikel
|
| 58 |
Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
|
Skarlos, D.V.
|
|
|
12 |
9 |
p. 1231-1238
|
artikel
|
| 59 |
Randomized comparison of early versus late hyperfractionatedthoracic irradiation concurrently with chemotherapy in limited diseasesmall-cell lung cancer: A randomized phase II study of the HellenicCooperative Oncology Group (HeCOG)
|
D. V. Skarlos
|
|
2001
|
12 |
9 |
p. 1231-1238
8 p.
|
artikel
|
| 60 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
|
O’Shaughnessy, J.A.
|
|
|
12 |
9 |
p. 1247-1254
|
artikel
|
| 61 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
|
J. A. OShaughnessy
|
|
2001
|
12 |
9 |
p. 1247-1254
8 p.
|
artikel
|
| 62 |
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
|
Di Paolo, A.
|
|
|
12 |
9 |
p. 1301-1306
|
artikel
|
| 63 |
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
|
A. Di Paolo
|
|
2001
|
12 |
9 |
p. 1301-1306
6 p.
|
artikel
|
| 64 |
Repetita iuvant – INTACC (Intergruppo Italiano Terapia Adiuvante Carcinoma del Colon)
|
Di Costanzo, F.
|
|
|
12 |
9 |
p. 1331
|
artikel
|
| 65 |
Repetita iuvant INTACC (Intergruppo Italiano Terapia Adiuvante Carcinoma del Colon)
|
F. Di Costanzo
|
|
2001
|
12 |
9 |
p. 1331-1331
1 p.
|
artikel
|
| 66 |
Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma
|
Edwards, M.J.J.
|
|
|
12 |
9 |
p. 1327-1329
|
artikel
|
| 67 |
Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma
|
M. J. J. Edwards
|
|
2001
|
12 |
9 |
p. 1327-1329
3 p.
|
artikel
|
| 68 |
Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes
|
Zelek, L.
|
|
|
12 |
9 |
p. 1265-1268
|
artikel
|
| 69 |
Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes
|
L. Zelek
|
|
2001
|
12 |
9 |
p. 1265-1268
4 p.
|
artikel
|
| 70 |
Small-cell carcinoma of the esophagus: Report of three cases and review of the literature with emphasis on therapy
|
Madroszyk, A.
|
|
|
12 |
9 |
p. 1321-1325
|
artikel
|
| 71 |
Small-cell carcinoma of the esophagus: Report of three cases and review of the literature with emphasis on therapy
|
A. Madroszyk
|
|
2001
|
12 |
9 |
p. 1321-1325
5 p.
|
artikel
|
| 72 |
The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma
|
Soini, Y.
|
|
|
12 |
9 |
p. 1239-1245
|
artikel
|
| 73 |
The expression of P-glycoprotein and multidrug resistance proteins 1 and2 (MRP1 and MRP2) in human malignant mesothelioma
|
Y. Soini
|
|
2001
|
12 |
9 |
p. 1239-1245
7 p.
|
artikel
|
| 74 |
The potential and pitfalls for developing guidelines in oncology
|
Austoker, J.
|
|
|
12 |
9 |
p. 1189-1190
|
artikel
|
| 75 |
The potential and pitfalls for developing guidelines in oncology
|
J. Austoker
|
|
2001
|
12 |
9 |
p. 1189-1190
2 p.
|
artikel
|
| 76 |
There are unsafe places, but may be there is more to it than that…
|
|
|
|
12 |
9 |
p. 1185
|
artikel
|
| 77 |
This letter was referred to the author, who responds as follows:
|
Wils, J.
|
|
|
12 |
9 |
p. 1331
|
artikel
|
| 78 |
This letter was referred to the author, who responds as follows
|
J. Wils
|
|
2001
|
12 |
9 |
p. 1331-1331
1 p.
|
artikel
|
| 79 |
Undertreating cancer pain is a crime
|
|
|
|
12 |
9 |
p. 1185
|
artikel
|
| 80 |
V. T. DeVita, S. Hellman & S. A. Rosenberg (eds). Progress in Oncology 2001
|
C. J. A. Punt
|
|
2001
|
12 |
9 |
p. 1332-1332
1 p.
|
artikel
|
| 81 |
Wisdom word
|
|
|
|
12 |
9 |
p. 1183
|
artikel
|
| 82 |
Wisdom wordAre drug companies manipulating publications?How the fascination of cannabis misleads journalists.Patients become anxious and medical care team is overwhelmed: Anxiety abouttamoxifen once again.Annals is going well.Americans may finally be reimbursed by Medicare for oral chemotherapy.If this was our only anxiety about our adolescent kids?And which will be the next drug to go out of the market?Difficult times at Johns Hopkins.There are unsafe places, but maybe there is more to it than that...Undertreating cancer pain is a crime.Perhaps not everyone knows that...
|
|
|
2001
|
12 |
9 |
p. 1183-1187
5 p.
|
artikel
|
Tijdschrift beschrijving